Almirall, S.A. (ALMRY) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Almiral 9-month 2025 Financial Results and Business Update conference call and webcast. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be the question and answer session. To ask a question during the session, you need to press star, 1, 1 on your telephone keypad. You will not hear an automated message advising your hand is raised. To withdraw a question, please press star, 1, and 1 again. Please be advised that today's conference has been recorded. I would now like to hand the conference over to our first speaker today, Pablo Divasson, Head of IR. Please go ahead, sir. Thank you very much, Nadia, and good morning, everyone. Thank you for joining us for today's quarterly earnings update and review of Almiral's nine-month balance of results of 2025. As always, we are sharing the slides we are using today in the investor section of our website at almiral.com. Please move to slide number two. Let me remind you that the information presented in this call contains forward-looking statements, which involve known and unknown risk, uncertainties, and other factors that may cause actual results to materially differ from what we are sharing today. Please move to slide number three. Presenting today, we have Carlos Ayala, Chairman and Chief Executive Officer. John Garay, Chief Financial Officer, and Carl Sigalán, Chief Scientific Officer. Carlos will start with the business highlights covering the first nine months of 2025, followed by an update specifically on biologics and the key growth drivers of our medical dermatology platform. Carl will provide you with an R&D status update presenting our pilot. We then talk to you through the financial before Carlos concludes the ...